Skystar Bio-Pharmaceutical Company (SKBI) 0.2300

New Post Public Reply Private Reply Replies (0) Message Board

Sep 3, 2016 at 7:22 PM

Skystar Bio-Pharmaceutical Company (SKBI) 0.2300 $SKBI

Skystar Bio-Pharmaceutical Company Update
Marketwired - Tue Dec 22, 9:17AM CST
Skystar Bio-Pharmaceutical Company (OTCQB: SKBI), a China-based manufacturer and distributor of veterinary medicine, vaccines, micro-organisms and feed additives, announced that while the Company trades on the over-the-counter market, it has made progress with its audits.

Skystar Bio-Pharmaceutical Company Announces Delisting From NASDAQ
Marketwired - Fri Dec 18, 3:30PM CST
Skystar Bio-Pharmaceutical Company (NASDAQ: SKBI), a China-based manufacturer and distributor of veterinary medicine, vaccines, micro-organisms and feed additives, announced that on December 17, 2015, Skystar Bio-Pharmaceutical Company (the "Company"

received notification from The Nasdaq Stock Market ("Nasdaq"

informing the Company that a Nasdaq hearing panel had decided to delist the Company's shares from Nasdaq and that the Company's shares would be suspended from trading on Nasdaq at the open of business on December 21, 2015.

Skystar Bio-Pharmaceutical Company Announces Receipt of Nasdaq Notification Letter
Marketwired - Thu Nov 19, 10:57AM CST
Skystar Bio-Pharmaceutical Company (NASDAQ: SKBI), a China-based manufacturer and distributor of veterinary medicine, vaccines, micro-organisms and feed additives, announced that on November 17, 2015, it received a letter from NASDAQ Stock Market indicating that that Skystar failed to comply with Nasdaq's filing requirement set forth in Listing Rule 5250(c)(1) (the "Rule"

because it failed to file its Form 10-Q for the fiscal quarter ended September 30, 2015 (the "Quarterly Report"

.

Skystar Bio-Pharmaceutical Company Request to Stay Nasdaq Trading Suspension Granted
Marketwired - Fri Nov 06, 8:00AM CST
Skystar Bio-Pharmaceutical Company (NASDAQ: SKBI), a China-based manufacturer and distributor of veterinary medicine, vaccines, micro-organisms and feed additives, announced today that on November 4, 2015 it received a letter from the Nasdaq Hearings Panel that granted the request of Skystar Bio-Pharmaceutical Company to extend the automatic 15-day stay of suspension from The Nasdaq Stock Market, until the hearing on the merits scheduled for December 3, 2015, and a determination regarding the Company's listing status.

Skystar Bio-Pharmaceutical Company Provides Investor Update Regarding Delay in Filing Form 10-K
Marketwired - Fri Oct 02, 8:30AM CDT
Skystar Bio-Pharmaceutical Company (NASDAQ: SKBI) (the "Company"

, a China-based manufacturer and distributor of veterinary medicine, vaccines, micro-organisms and feed additives, announced that it has conferred with Crowe Horwath, HK, the Company's appointed auditor in relation to the completion of Skystar's audit for the year ended December 31, 2014 and the review of the Company's financial statements for the quarters ended March 31, 2015 and June 30, 2015. Based on those communications, Skystar believes that Crowe Horwath is in the process of completing its audit of the Company's financial statements for the year ended December 31, 2014.

Skystar Bio-Pharmaceutical Company Announces Receipt of Nasdaq Non-Compliance Letter Due to Delay in Filing Form 10-Q
Marketwired - Tue Aug 25, 3:15PM CDT
Skystar Bio-Pharmaceutical Company (NASDAQ: SKBI) (the "Company"

, a China-based manufacturer and distributor of veterinary medicine, vaccines, micro-organisms and feed additives, announced today that on August 19, 2015, the Company received a notification from the Nasdaq Stock Market ("Nasdaq"

informing the Company that because it had not filed its Quarterly Report on Form 10-Q for the quarter ended June 30, 2015, the Company was not in compliance with Nasdaq Listing Rule 5250(c)(1). The Company previously submitted a plan of compliance to Nasdaq, responded to an initial request for additional information from Nasdaq, and is preparing responses to a second request for additional information from Nasdaq. If its plan is approved by the Nasdaq staff, the Company may be eligible for a listing exception of up to 180 calendar days from the date of its initial delinquent filing (its Annual Report on Form 10-K for the year ended December 31, 2014), or until October 12, 2015, to regain compliance.

Skystar Bio-Pharmaceutical Company Announces Submission of Plan of Compliance With Nasdaq
Marketwired - Mon Jun 15, 9:32PM CDT
Skystar Bio-Pharmaceutical Company (NASDAQ: SKBI) (the "Company"

, a China-based manufacturer and distributor of veterinary medicine, vaccines, micro-organisms and feed additives, announced today that the Company timely submitted a "Plan of Compliance" to Nasdaq in accordance with applicable Nasdaq rules. The Plan of Compliance sets out the Company's plan to regain compliance with Nasdaq's continued listing rules.

Skystar Bio-Pharmaceutical Company Announces Receipt of NASDAQ Non-Compliance Letter Due to Delay in Filing Form 10-K
Marketwired - Wed Apr 15, 4:00PM CDT
Skystar Bio-Pharmaceutical Company (NASDAQ: SKBI), a China-based manufacturer and distributor of veterinary medicine, vaccines, micro-organisms and feed additives, announced today that the Company received a notification from the Nasdaq Stock Market ("Nasdaq"

informing the Company that since it had not filed its Annual Report on Form 10-K for the fiscal year ended December 31, 2014, the Company was not in compliance with Nasdaq Listing Rule 5250(c)(1). The Nasdaq notification letter does not result in the immediate delisting of the Company's common stock, and the stock will continue to trade uninterrupted under its current trading symbol.

Skystar Bio-Pharmaceutical Reports Third Quarter Fiscal Year 2014 Financial Results
Marketwired - Fri Nov 14, 4:01PM CST
Skystar Bio-Pharmaceutical Company (NASDAQ: SKBI) ("Skystar" or the "Company"

, a China-based manufacturer and distributor of veterinary medicine, vaccines, micro-organisms and feed additives, today reported unaudited third quarter fiscal year 2014 earnings, for the period ended September 30, 2014.

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

First Horizon's $25M Bet: New Center Transforms Houston

New Markets Tax Credits: A Game Changer First things first, if you're thinking this is some typical charitable write-off, think again. First Horizon Bank (NYSE: FHN) is deep in the mix of something pretty transformative in the world of finance and community support. They're not just throwing money at a problem and hoping it sticks. Nope, we're talking real strategy with a...

ACME's AI Innovation Shakes Up Filmmaking Scene

The Game-Changer in Virtual Production You ever hear about the Grey Box™ phenomenon? Sounds like a sci-fi gizmo, right? Turns out, it's the real deal and ACME Media's been riding this revolutionary wave straight to the top of the film industry ladder. Their approach with this AI-driven gizmo isn't just about cutting-edge tech wizardry—it's reimagining how we shoot...

Citigroup, Scotia Aid TSTT in $500M Note Offering

Kicking off with a banger that’s got financial water coolers buzzing, Greenberg Traurig just pulled a rabbit out of the hat helping Citigroup and Scotia Capital orchestrate a chunky near $500 million dual-currency notes deal for Telecommunications Services of Trinidad and Tobago Limited (TSTT). Now, this isn’t your run-of-the-mill market maneuver. We're seeing a...

Toys"R"Us Rolls Out 160 U.S. Stores, NYC Celebration

Rebuilding the Toy Empire After a rough few years, Toys"R"Us is clawing its way back into the hearts—and wallets—of American shoppers. With 160+ new standalone stores popping up like mushrooms after rain, these guys aren't just playing games. This is a strategic move to reestablish their presence in the retail landscape just before the holiday shopping frenzy kicks...

Terra Kaffe's Big Win with Oprah's Endorsement

Terra Kaffe Hits the Jackpot with Oprah Sometimes, destiny has a way of handing out golden tickets, and for Terra Kaffe, receiving a nod from Oprah Winfrey's revered list of Favorite Things for 2026 is nothing short of that. I mean, you can't underestimate the pull Mrs. O has. Her endorsement isn’t just another celebrity pat-on-the-back, it’s a megaphone blaring...

CVRx Faces Legal Storm: Investors Grapple with Fallout

CVRx in the Crosshairs: Legal and Operational Woes There's a storm brewing over at CVRx, Inc. (NASDAQ: CVRX), and it's pulling investors down a hell of a financial rabbit hole. You might think you're in the clear with a company like CVRx that boasts approved devices, but think again. Recent revelations have shown that even those with FDA stamps aren't immune to the...

YYForce Expands in UAE with Key Hospitality Wins

Unveiling YYForce's Middle East Strategy Smack in the middle of an aggressive Middle Eastern expansion, YYForce (NASDAQ: YFOR) is making waves with some new headline-grabbing contracts in the UAE. This ain't just a side hustle—it's big time. They're planting their flag across the luxury hospitality sector like they're going for a moon landing. The recent announcement...

Immunic, Inc. Steams Ahead: Phase 3 Trials Hinge on MS Data

A Pivotal Moment for Immunic We’re staring down a critical December for Immunic, Inc. as they trot out top-line data for their Phase 3 ENSURE trials aimed at relapsing multiple sclerosis (MS). Now, I’m all ears wondering if those trials can hold water — success could morph them from a tinkering biotech into a commercial giant. For market vultures like us,...

CR&R Workers Join Teamsters, Fight for Fair Conditions

Waste Workers Push Back Against Corporate Pressure The Southern California sun isn't the only thing heating up these days; the waste workers at CR&R Environmental Services have cranked up the heat by voting to join Teamsters Local 396. It's like Groundhog Day in the world of labor rights—same story, different locale, workers banding together for a fair shot. A Stand...

Kentucky Power's Bold Plan to Boost Local Economy

Electricity, Economy, and Execution Kentucky Power just laid out plans that could massively swing the pendulum for eastern Kentucky's economic prospects. They've put filings on the table for the Kentucky Public Service Commission that, if approved, promise big economic benefits. We're talking about a potential infusion of $500 million through fixed-rate offsets and an...